Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Deciding Between Adjuvant Targeted Therapy and Immunotherapy in BRAF+ Melanoma

January 22nd 2021

Reinhard Dummer, MD, shares his approach for selecting between targeted approaches and immunotherapy agents in the adjuvant treatment of patients with melanoma.

Molecular Testing in Metastatic Melanoma

January 22nd 2021

The Role of COVID-19 in Adjuvant Treatment Decisions in Melanoma

January 22nd 2021

PFS Deserves More Than Surrogate Status as a Clinical Trial End Point

January 20th 2021

Although recent benefits do not pertain to all cancers and “cure” remains a relatively uncommon event, oncologists have an increasing number of molecularly targeted and immunotherapeutic strategies to employ based on objectively meaningful clinical trial outcomes.

Treatment Goals and Patient Decisions in Melanoma

January 15th 2021

A Look at the KEYNOTE-054 and COMBI-AD Data

January 15th 2021

Dr. Sullivan on Sequencing Targeted Therapy and Immunotherapy in Melanoma

January 13th 2021

Ryan Sullivan, MD, discusses treatment sequencing with targeted therapy and immunotherapy in melanoma.

Dr. Sznol on the Multidisciplinary Management of Immunotherapy-Associated Toxicities in Melanoma

January 11th 2021

Mario Sznol, MD, Yale Cancer Center, discusses the multidisciplinary management of toxicities associated with immunotherapy in patients with melanoma.

FDA Grants Fast Track Status to Cavrotolimod for Merkel Cell Carcinoma, CSCC

January 11th 2021

January 11, 2021 - The FDA has granted fast track designations to cavrotolimod for use in combination with a PD-1 therapy in patients with locally advanced or metastatic Merkel cell carcinoma that is refractory to previous PD-1 blockade and for use in combination with a PD-1/PD-L1 agent in those with advanced or metastatic cutaneous squamous cell carcinoma that is refractory to previous PD-1/PD-L1 blockade.

FDA Grants Orphan Drug Designation to PVSRIPO for Advanced Melanoma

January 11th 2021

January 11, 2021 — The FDA has granted an orphan drug designation to the novel intratumoral immunotherapy agent PVSRIPO for the treatment of patients with advanced melanoma, specifically those with stage IIIB-IV disease.

Testing and BRAF Mutations in Melanoma

January 8th 2021

Introduction to Melanoma

January 8th 2021

Dr. Sznol on Toxicities Associated With Immunotherapy in Melanoma

January 7th 2021

Mario Sznol, MD, discusses toxicities associated with immunotherapy in patients with melanoma.

Dr. Luke on Predictive Versus Prognostic Biomarkers in Melanoma

January 6th 2021

Jason J. Luke, MD, FACP, compares predictive and prognostic biomarkers in melanoma.

STP705 Achieves High Rates of Histological Clearance in Squamous Cell Skin Cancer

December 22nd 2020

The small interfering RNA therapeutic STP705 has been found to induce high rates of histological clearance with a favorable toxicity profile in patients with squamous cell skin cancer.

Updates and Advances in Basal Cell Carcinoma

December 18th 2020

Although basal cell carcinoma generally has a good prognosis, improving tolerance to targeted Hedgehog inhibitors and optimizing second-line treatment with immune checkpoint inhibitors are important for the small subset of patients who develop locally advanced or metastatic disease.

Dr. Sznol on the Challenges of Managing Immune-Related Toxicities in Melanoma

December 16th 2020

Mario Sznol, MD, discusses the challenges of managing immune-related toxicities in melanoma.

Nivolumab/Ipilimumab Combo Shows Antitumor Activity in Metastatic Uveal Melanoma

December 16th 2020

December 16, 2020 — The combination of nivolumab with ipilimumab demonstrated activity in patients with metastatic uveal melanoma with encouraging responses.

Dr. Atkins on the Benefits of Neoadjuvant Therapy in Melanoma

December 15th 2020

Michael B. Atkins, MD, discusses the benefits of neoadjuvant therapy in melanoma.

Dr. Sullivan on Treatment Options in BRAF-Mutant Melanoma

December 15th 2020

Ryan Sullivan, MD, discusses treatment options in BRAF-mutant melanoma.